Pricing Log in Create free account
Friday 6 November 2026 Export ZLAB’s income statement to Excel — free account

Zai Lab Limited Unsponsored ADR

ZLAB Healthcare Biotechnology

Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.

Revenue
−6.79%
EPS
−24.3%
Free cash flow
−95.5%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

25.12 2.52 +11.15%
Market cap
$2.6B
P/E
0.0×
Fwd P/E
−10.0×
Dividend yield
—
F-score
4/9
Altman Z
−0.24
Beneish M
−2.35
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Zai Lab Limited Unsponsored ADR (ZLAB) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Zai Lab Limited Unsponsored ADR (ZLAB) trades at a EV/Sales of 4.7×. Over the past ten years it has ranged from 0.0× (December 2019) to 422× (February 2020); the current reading is higher than 41% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 2.9× (36.64%)
FY2024 4.6× (28.30%)
FY2023 6.4× (29.05%)
FY2022 9.1× (70.49%)
FY2021 30.8× (81.13%)
FY2020 163× (40.04%)
FY2019 272× —
FY2018 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 5.6× 53.46%
Jun 2026 3.7× 7.86%
Mar 2026 3.4× 15.71%
Dec 2025 2.9× (58.57%)
27 more quarters

Against its own ten years

Low 0.0× High 422×
Ten-year median 6.0×
Current reading's percentile 21

EV/Sales against peers

Company EV/Sales
PHVS Pharvaris N.V. compare n/m
MBX MBX Biosciences, Inc. compare n/m
ZLAB Zai Lab Limited Unsponsored ADR 4.7×
ADMA ADMA Biologics Inc compare 5.8×
RCUS Arcus Biosciences, Inc. compare 17.5×
RXRX Recursion Pharmaceuticals, Inc. compare 19.8×
XNCR Xencor, Inc. compare 21.6×
NAMS NewAmsterdam Pharma Company N.V. compare 66.6×
CLDX Celldex Therapeutics, Inc. compare 1,691×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ZLAB